Novacyt Stock Shares Owned By Insiders

Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Based on the latest financial disclosure, 3.49% of Novacyt are shares owned by insiders. This is 77.01% lower than that of the Biotechnology sector and 75.39% lower than that of the Health Care industry. The shares owned by insiders for all France stocks is 65.41% higher than that of the company.

The Macroaxis Fundamental Analysis modules help investors analyze Novacyt's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novacyt using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novacyt based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

When running Novacyt's price analysis, check to measure Novacyt's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt is operating at the current time. Most of Novacyt's value examination focuses on studying past and present price action to predict the probability of Novacyt's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt's price. Additionally, you may evaluate how the addition of Novacyt to your portfolios can decrease your overall portfolio volatility.